Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 6/20 | 0.38 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9889757 | 1.00 | EPHX1 (0.50) | EPHX1FAAHMAPTTP53CES1 | |
| SCHEMBL11084948 | 1.00 | EPHX1 (0.50) | EPHX1FAAHMAPTTP53CES1 | |
| SCHEMBL9889756 | 0.98 | EPHX1 (0.47) | EPHX1FAAHMAPTTP53CES1 | |
| SCHEMBL2199927 | 0.91 | EPHX1 (0.44) | EPHX1FAAHTP53CES1CES2 | |
| SCHEMBL29089205 | 0.91 | SLC22A1 (0.45) | EPHX1FAAHTP53 | |
| Pyridine SCHEMBL22265261 | 0.85 | EPHX1 (0.39) | EPHX1FAAHMAPTTP53GPR84 | |
| SCHEMBL24667466 | 0.83 | EPHX1 (0.46) | EPHX1FAAHMAPTTP53CES1 | |
| SCHEMBL2205397 | 0.82 | EPHX1 (0.39) | EPHX1FAAHMAPTTP53CES1 | |
| SCHEMBL17092518 | 0.80 | EPHX1 (0.40) | EPHX1FAAHMAPTTP53CES1 | |
| SCHEMBL18598823 | 0.79 | EPHX1 (0.31) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512070-B2 | Method for producing compound containing BIS (perfluoroalkylsulfonyl) methyl group and salt thereof, and solid electrolyte membrane produced using same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20150266816-A1 | Method for Producing Compound Containing BIS (Perfluoroalkylsulfonyl) Methyl Group and Salt Thereof, and Solid Electrolyte Membrane Produced Using Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2012043619-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | セントラル硝子株式会社 (JP) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266816-A1 | Method for Producing Compound Containing BIS (Perfluoroalkylsulfonyl) Methyl Group and Salt Thereof, and Solid Electrolyte Membrane Produced Using Same | PFAS, FRK, AFF4 | EPHX1 2013/4885FAAH 1023/4885MAPT 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.